Safety and effectiveness of insulin detemir in different age-groups in the a1chieve study.

ABSTRACT:

Introduction

Diabetes therapy should balance glycemic control with risk of adverse events. This sub-analysis of the A1chieve study evaluated clinical safety and effectiveness of insulin detemir in different age-groups (≤40 years, >40-65 years, and >65 years) of insulin-experienced and insulin-naïve people with type 2 diabetes.

Methods

A1chieve was an international, open-label, non-interventional, 24-week study in 66,726 people with type 2 diabetes starting/switching to therapy with biphasic insulin aspart 30, insulin detemir or insulin aspart (alone/in combination) in routine clinical practice. This sub-analysis evaluated clinical safety and effectiveness in patients starting/switching to insulin detemir (±oral glucose-lowering drugs).

Results

In total, 15,241 patient

SUBMITTER: Malek R 

PROVIDER: S-EPMC3687092 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature